**REGISTERED COMPANY NUMBER: 08082786 (England and Wales) REGISTERED CHARITY NUMBER: 1150234** ## **REPORT OF THE TRUSTEES AND** ## **FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023** ## **FOR BRITISH NUCLEAR MEDICINE SOCIETY** E R Grove & Co Limited Grove House Coombs Wood Court Steel Park Road Halesowen West Midlands B62 8BF **BRITISH NUCLEAR MEDICINE SOCIETY** ## **CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023** |||**Page**|| |---|---|---|---| |**Report of the Trustees**|1|to|3| |**Independent Examiner's Report**||4|| |**Statement of Financial Activities**||5|| |**Balance Sheet**||6|| |**Cash Flow Statement**||7|| |**Notes to the Cash Flow Statement**||8|| |**Notes to the Financial Statements**|9|to|14| |**Detailed Statement of Financial Activities**|15|to|16| ## **BRITISH NUCLEAR MEDICINE SOCIETY** ## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023** The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019). ## **OBJECTIVES AND ACTIVITIES** ## **Objectives and aims** British Nuclear Medicine Society is dedicated to promoting the multidisciplinary practice of high quality nuclear medicine for the benefit of patients. The specific objectives of the British Nuclear Medicine Society are to: 1 Raise the profile of nuclear medicine 2 Engage with all health care providers involved in the clinical use of radionuclides 3 Provide a forum for the communication of advances in nuclear medicine 4 Provide resources and encourage the provision of education and training to support continuing professional development. 5 Represent nuclear medicine with official bodies and on advisory committees 6 Develop and promote standards and guidelines for the safe and effective practice of nuclear medicine 7 Promote nuclear medicine research and development 8 Improve the level of support to isolated departments 9 Provide greater information for the benefit of patients 10 Promote and support the recertification/revalidation of practitioners 11 Maintain an appropriate charitable status. ## **Significant activities** In order for the charity to achieve its aim BNMS engage in the following activities: - Raising the profile of nuclear medicine through the website, scientific meetings and attendance of careers fairs. - Engaging with other professional organisations, including British Institute of Radiology, British Cardiology Society, Institute of Physics and Engineering in Medicine, Royal College of Physicians, Royal College of Radiologists, Royal College of Surgeons, Royal College of Nursing, Society and College of Radiographers and Society of Radiological Protection. - Providing a forum for the communication of advances in nuclear medicine through annual and regional scientific meetings, Nuclear Medicine Communications (the official BNMS journal) and the BNMS website. - Leading in the provision of education and training to support the development of nuclear medicine - Representing the specialty on relevant official bodies and advisory committees - Developing and promoting standards and guidelines for the safe practice of nuclear medicine. - Promoting nuclear medicine research and development by engaging with academic institutions and industry to promote research leading to new developments and improvements in clinical practice. ## **Public benefit** The public benefits from the activities of the British Nuclear Medicine Society through the pursuit of its specific objectives including the development and promotion of standards and guidelines for the safe and effective practice of nuclear medicine, the promotion of nuclear medicine research and development and the provision of greater information for the public on the BNMS website. Page 1 ## **BRITISH NUCLEAR MEDICINE SOCIETY** ## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023** ## **ACHIEVEMENT AND PERFORMANCE** ## **Charitable activities** The British Nuclear Medicine Society held three scientific and educational meetings this year around the UK, the results of which are as follows: ||**Spring**|**Autumn**|**Online**|| |---|---|---|---|---| ||**Harrogate**|**London**|**Educational**|**Total**| ||**£**|**£**|**£**|**£**| |||||| |**Income**||||| |Commercial exhibition income|159,973|26,048|1,000|187,021| |Annual conference delegate registration fees|105,468|25,466|17,546|148,480| |||||| ||265,441|51,514|18,546|335,501| |Less: Scientific meeting expenses|187.789|43,683|7,135|238,607| |||||| |Surplus|77,652|7,831|11,411|96,894| |||||| ## **Fundraising activities** The British Nuclear Medicine Society generates income from membership fees, from royalties received through "Nuclear Medicine Communications" (the scientific journal of the BNMS) as well registration and exhibitor fees from those attendees at the annual and educational meetings of the Society. ## **FUTURE PLANS** The society will continue to promote the multidisciplinary practice of nuclear medicine for the benefit of patients. It plans to continue holding regular meetings throughout the country and will further encourage regional networks. ## **STRUCTURE, GOVERNANCE AND MANAGEMENT Governing document** The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. ## **REFERENCE AND ADMINISTRATIVE DETAILS Registered Company number** 08082786 (England and Wales) **Registered Charity number** 1150234 ## **Registered office** Royal College of Physicians 11 St Andrews Place Regents Park London NW1 4LE ## **Trustees** Who are also directors Mrs J Croasdale Dr R Graham Dr S Redman Dr J R Buscombe (Resigned 17 May 22) Mr C S Kalirai (appointed 17 May 22) Radiopharmacist Radiologist Radiologist Nuclear Medicine Physician Clinical Scientist ## **Independent Examiner** E R Grove & Co Limited Grove House Coombs Wood Court Steel Park Road Halesowen West Midlands B62 8BF Approved by order of the board of trustees on 8 May 2024 and signed on its behalf by: Page 2 **BRITISH NUCLEAR MEDICINE SOCIETY** ## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023** Mr C S Kalirai - Trustee Page 3 ## **INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF BRITISH NUCLEAR MEDICINE SOCIETY** ## **Independent examiner's report to the trustees of British Nuclear Medicine Society ('the Company')** I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2023. ## **Responsibilities and basis of report** As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act'). Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act. ## **Independent examiner's statement** Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies. I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe: 1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or 2. the accounts do not accord with those records; or 3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or 4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)). I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. Steven Lomas E R Grove & Co Limited Grove House Coombs Wood Court Steel Park Road Halesowen West Midlands B62 8BF 8 May 2024 Page 4 ## **BRITISH NUCLEAR MEDICINE SOCIETY** ## **STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2023** |Unrestricted
Restricted
fund
fund
Notes
£
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
2
4,400
-
Other trading activities
3
412,849
(83)
Investment income
4
5,768
165
Other income
90,564
-
**Total**
513,581
82
**EXPENDITURE ON**
Raising funds
5
422,080
217
**NET INCOME/(EXPENDITURE)**
91,501
(135)
**RECONCILIATION OF FUNDS**
Total funds brought forward
390,382
14,408
**TOTAL FUNDS CARRIED FORWARD**
481,883
14,273|2023
Total
funds
£
4,400
412,766
5,933
90,564
513,663
422,297
91,366
404,790
496,156|2022
Total
funds
£
3,500
319,943
1,706
64,036| |---|---|---| |||389,185| |||339,483| |||49,702
355,088| |||404,790| The notes form part of these financial statements Page 5 ## **BRITISH NUCLEAR MEDICINE SOCIETY** ## **BALANCE SHEET 31 DECEMBER 2023** |Unrestricted
Restricted
fund
fund
Notes
£
£
**FIXED ASSETS**
Tangible assets
11
2,415
-
**CURRENT ASSETS**
Debtors
12
168,525
-
Cash at bank
418,872
14,273
587,397
14,273
**CREDITORS**
Amounts falling due within one year
13
(107,929)
-
**NET CURRENT ASSETS**
479,468
14,273
**TOTAL ASSETS LESS CURRENT LIABILITIES**
481,883
14,273
**NET ASSETS**
481,883
14,273
**FUNDS**
14
Unrestricted funds
Restricted funds
**TOTAL FUNDS**|2023
Total
funds
£
2,415
168,525
433,145
601,670
(107,929)
493,741
496,156
496,156
481,883
14,273
496,156|2022
Total
funds
£
3,129
189,273
346,722
535,995
(134,334)
401,661
404,790
404,790
390,382
14,408
404,790| |---|---|---| The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023. The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006. The trustees acknowledge their responsibilities for - (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and - (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company. These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime. The financial statements were approved by the Board of Trustees and authorised for issue on 8 May 2024 and were signed on its behalf by: Mr C S Kalirai - Trustee The notes form part of these financial statements Page 6 ## **BRITISH NUCLEAR MEDICINE SOCIETY** ## **CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2023** |Notes
**Cash flows from operating activities**
Cash generated from operations
1
Net cash provided by operating activities
**Cash flows from investing activities**
Purchase of tangible fixed assets
Interest received
Net cash provided by investing activities
**Change in cash and cash equivalents in**
**the reporting period**
**Cash and cash equivalents at the**
**beginning of the reporting period**
**Cash and cash equivalents at the end of**
**the reporting period**|2023
£
80,923
80,923
(433)
5,933
5,500
86,423
346,722
433,145|2022
£
90,998| |---|---|---| |||90,998| |||-
1,706| |||1,706| |||| |||92,704
254,018| |||346,722| The notes form part of these financial statements Page 7 ## **BRITISH NUCLEAR MEDICINE SOCIETY** ## **NOTES TO THE CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2023** |**1.**
**RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES**
2023
£
**Net income for the reporting period (as per the Statement of Financial**
**Activities)**
91,366
**Adjustments for:**
Depreciation charges
1,147
Interest received
(5,933)
Decrease in debtors
20,748
(Decrease)/increase in creditors
(26,405)
**Net cash provided by operations**
80,923|2022
£
49,702
1,494
(1,706)
14,638
26,870
90,998| |---|---| ## **2. ANALYSIS OF CHANGES IN NET FUNDS** ||At 1.1.23|Cash flow|At 31.12.23| |---|---|---|---| ||£|£|£| |**Net cash**|||| |Cash at bank|346,722|86,423|433,145| ||346,722|86,423|433,145| |**Total**|346,722|86,423|433,145| The notes form part of these financial statements Page 8 **BRITISH NUCLEAR MEDICINE SOCIETY** ## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023** ## **1. ACCOUNTING POLICIES** ## **Basis of preparing the financial statements** The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention. ## **Income** All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably. Exhibition income is recognised in the Statement of Financial Activities in the year that the exhibition is held. Grants and donations are only recognised in the statement of Financial Activity when the charity has unconditional entitlement to the resources. Where the donor imposes conditions that the resource is expended in a future accounting period, income is recorded as deferred income at the balance sheet date and a creditor is included under deferred income. ## **Expenditure** Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. Exhibition expense are recognised in the Statement of Financial Activities in the year that the exhibition is held. ## **Tangible fixed assets** Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life. Fixtures and fittings - 15% on reducing balance Computer equipment - 33% on reducing balance ## **Taxation** The charity is exempt from corporation tax on its charitable activities. ## **Fund accounting** Unrestricted funds are available of use at the discretion of the trustees In furtherance of the general objectives of the charity and which have not been designated for other purposes. Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by the Charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. Further explanation of the nature and purpose of each fund is included in the notes to the financial statements. ## **Pension costs and other post-retirement benefits** The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate. Page 9 continued... ## **BRITISH NUCLEAR MEDICINE SOCIETY** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2023** |**2.**|**DONATIONS AND LEGACIES**|||||| |---|---|---|---|---|---|---| ||||||2023|2022| ||||||£|£| ||Donations||||4,400|3,500| |**3.**|**OTHER TRADING ACTIVITIES**|||||| ||||||2023|2022| ||||||£|£| ||Commercial exhibition income||||187,021|148,658| ||Annual conference delegate registration fees||||148,480|98,356| ||Commission received||||4,124|169| ||Royalties received||||71,861|72,760| ||Other project income||||1,280|-| ||||||412,766|319,943| |**4.**|**INVESTMENT INCOME**|||||| ||||||2023|2022| ||||||£|£| ||Deposit account interest||||5,933|1,706| |**5.**|**RAISING FUNDS**|||||| ||**Raising donations and legacies**|||||| ||||||2023|2022| ||||||£|£| ||Support costs||||141,820|106,165| ||**Other trading activities**|||||| ||||||2023|2022| ||||||£|£| ||Purchases||||239,557|189,112| ||Awards and prizes||||1,432|775| ||Journal subscriptions||||39,488|43,431| ||||||280,477|233,318| ||Aggregate amounts||||422,297|339,483| |**6.**|**SUPPORT COSTS**|||||| ||||||Governance|| |||Management|Finance|Other|costs|Totals| |||£|£|£|£|£| ||Raising donations and|||||| ||legacies|133,668|2,934|1,147|4,071|141,820| Page 10 continued... **BRITISH NUCLEAR MEDICINE SOCIETY** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2023** ## **7. NET INCOME/(EXPENDITURE)** Net income/(expenditure) is stated after charging/(crediting): ||2023|2022| |---|---|---| ||£|£| |Other assurance services|3,831|4,383| |Depreciation - owned assets|1,146|1,494| ## **8. TRUSTEES' REMUNERATION AND BENEFITS** There were no trustees' remuneration or other benefits for the year ended 31 December 2023 nor for the year ended 31 December 2022. ## **Trustees' expenses** Payments totalling £4,761 (2022: £1,645) were made to trustees to reimburse travel costs to conferences and council meetings. ## **9. STAFF COSTS** |Wages and salaries
Other pension costs|2023
£
86,558
3,079
89,637|2022
£
65,168
2,947| |---|---|---| |||68,115| The average monthly number of employees during the year was as follows: ||2023|2022| |---|---|---| |Administrative|3|2| No employees received emoluments in excess of £60,000. ## **10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES** |Unrestricted
fund
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
3,500
Other trading activities
319,943
Investment income
1,666
Other income
64,036
**Total**
389,145
**EXPENDITURE ON**
Raising funds
339,483
**NET INCOME**
49,662
**RECONCILIATION OF FUNDS**
Total funds brought forward
340,720
**TOTAL FUNDS CARRIED FORWARD**
390,382|Restricted
fund
£
-
-
40
-
40
-
40
14,368
14,408|Total
funds
£
3,500
319,943
1,706
64,036| |---|---|---| |||389,185| |||339,483| |||49,702
355,088| |||404,790| Page 11 continued... ## **BRITISH NUCLEAR MEDICINE SOCIETY** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2023** ## **11. TANGIBLE FIXED ASSETS** |**COST**
At 1 January 2023
Additions
At 31 December 2023
**DEPRECIATION**
At 1 January 2023
Charge for year
At 31 December 2023
**NET BOOK VALUE**
At 31 December 2023
At 31 December 2022
**12.**
**DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Trade debtors
Other debtors
Prepayments and accrued income
**13.**
**CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Trade creditors
Social security and other taxes
VAT
Other creditors
Accrued expenses
**14.**
**MOVEMENT IN FUNDS**
**Unrestricted funds**
General fund
**Restricted funds**
Ross Breen Fund
**TOTAL FUNDS**|Fixtures
and
Computer
fittings
equipment
£
£
905
30,102
-
432
905
30,534
685
27,193
33
1,113
718
28,306
187
2,228
220
2,909
2023
£
49,542
39,132
79,851
168,525
2023
£
4,160
1,959
13,989
82,440
5,381
107,929
Net
movement
At 1.1.23
in funds
£
£
390,382
91,501
14,408
(135)
404,790
91,366||Totals
£
31,007
432| |---|---|---|---| ||||31,439| ||||27,878
1,146| ||||29,024| ||||2,415| ||||3,129| ||||2022
£
70,732
40,428
78,113| |||189,273|| |||2022
£
5,897
2,177
20,665
100,959
4,636|| |||134,334|| |||At
31.12.23
£
481,883
14,273|| |||496,156|| Page 12 continued... ## **BRITISH NUCLEAR MEDICINE SOCIETY** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2023** ## **14. MOVEMENT IN FUNDS - continued** Net movement in funds, included in the above are as follows: ||Incoming|Resources|Movement| |---|---|---|---| ||resources|expended|in funds| ||£|£|£| |**Unrestricted funds**|||| |General fund|513,581|(422,080)|91,501| |**Restricted funds**|||| |Ross Breen Fund|82|(217)|(135)| |**TOTAL FUNDS**|513,663|(422,297)|91,366| ## **Comparatives for movement in funds** |**Unrestricted funds**
General fund
**Restricted funds**
Ross Breen Fund
**TOTAL FUNDS**|Net
movement
At 1.1.22
in funds
£
£
340,720
49,662
14,368
40
355,088
49,702|At
31.12.22
£
390,382
14,408| |---|---|---| |||404,790| Comparative net movement in funds, included in the above are as follows: |**Unrestricted funds**
General fund
**Restricted funds**
Ross Breen Fund
**TOTAL FUNDS**|Incoming
Resources
Movement
resources
expended
in funds
£
£
£
389,145
(339,483)
49,662
40
-
40
389,185
(339,483)
49,702| |---|---| A current year 12 months and prior year 12 months combined position is as follows: |**Unrestricted funds**
General fund
**Restricted funds**
Ross Breen Fund
**TOTAL FUNDS**|Net
movement
At 1.1.22
in funds
£
£
340,720
141,163
14,368
(95)
355,088
141,068|At
31.12.23
£
481,883
14,273| |---|---|---| |||496,156| Page 13 continued... **BRITISH NUCLEAR MEDICINE SOCIETY** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2023** ## **14. MOVEMENT IN FUNDS - continued** A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows: |**Unrestricted funds**
General fund
**Restricted funds**
Ross Breen Fund
**TOTAL FUNDS**|Incoming
Resources
Movement
resources
expended
in funds
£
£
£
902,726
(761,563)
141,163
122
(217)
(95)
902,848
(761,780)
141,068| |---|---| The Ros Breen Fund was established in memory of Ros Breen, who was Superintendent Radiographer in Nuclear Medicine at Southampton General Hospital. The fund is invested in a capital reserve bank account and the interest earned is then used to provide grants to members of the Technology Group. ## **15. RELATED PARTY DISCLOSURES** There were no related party transactions for the year ended 31 December 2023. Page 14 ## **BRITISH NUCLEAR MEDICINE SOCIETY** ## **DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2023** |**INCOME AND ENDOWMENTS**
**Donations and legacies**
Donations
**Other trading activities**
Commercial exhibition income
Annual conference delegate registration fees
Commission received
Royalties received
Other project income
**Investment income**
Deposit account interest
**Other income**
Members subscriptions
**Total incoming resources**
**EXPENDITURE**
**Other trading activities**
Scientific meeting expenses
Other project expenses
Awards and prizes
Journal subscriptions
**Support costs**
**Management**
Wages and social security
Pensions
Rent
Insurance
Subscriptions
Telephone
Postage and stationery
General meeting and travelling expenses
Sundries
Computer costs
Advertising and website costs
**Finance**
Bank charges
Direct debit processing costs
**Other**
Fixtures and fittings
Carried forward|2023
£
4,400
187,021
148,480
4,124
71,861
1,280
412,766
5,933
90,564
513,663
238,607
950
1,432
39,488
280,477
86,558
3,079
1,280
1,033
678
709
867
19,711
355
19,398
-
133,668
1,681
1,253
2,934
33
33|2022
£
3,500
148,658
98,356
169
72,760
-| |---|---|---| |||319,943
1,706
64,036| |||389,185
183,663
5,449
775
43,431| |||233,318
65,168
2,947
1,265
813
1,332
517
615
7,051
113
16,493
796| |||97,110
1,419
1,069| |||2,488
39
39| This page does not form part of the statutory financial statements Page 15 ## **BRITISH NUCLEAR MEDICINE SOCIETY** ## **DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2023** |**DETAILED STATEMENT OF FINANCIAL ACTIVITIES**
**FOR THE YEAR ENDED 31 DECEMBER 2023**||| |---|---|---| |**Other**
Brought forward
Computer equipment
**Governance costs**
Auditors' remuneration for non audit work
Professional charges
Payroll costs
Total resources expended
**Net income**|2023
£
33
1,114
1,147
3,831
-
240
4,071
422,297
91,366|2022
£
39
1,455| |||1,494
4,383
450
240| |||5,073| |||339,483| |||49,702| This page does not form part of the statutory financial statements Page 16